Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas

References

• A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909–3918.
   PubMed Web of Science ®Google Scholar
• Lymphoma Study Group of Japanese Pathologists. The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol Int 2000;50:696–702.
   PubMed Web of Science ®Google Scholar
• The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982;49:2112–2135.
   PubMed Web of Science ®Google Scholar
• Jaffe ES, Harris NL, Stein H, et al World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer Press; 2001.
   Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Habermann TM, Kurtin PJ, et al Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol 1997;15:2296–2301.
   PubMed Web of Science ®Google Scholar
• Sonnen R, Schmidt WP, Müller-Hermelink HK, Schmitz N. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol 2005;129:366–372.
   PubMed Web of Science ®Google Scholar
• López-Guillermo A, Cid J, Salar A, et al Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol 1998;9:849–855.
   PubMed Web of Science ®Google Scholar
• Shimoyama M, Ota K, Kikuchi M, et al Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M. J Clin Oncol 1988;6:128–141.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Brousse N, Peuchmaur M, et al Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. Ann Oncol 1990;1:45–50.
   PubMed Web of Science ®Google Scholar
• Melnyk A, Rodriguez A, Pugh WC, Cabannillas F. Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997;89:4514–4520.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Gaulard P, Lepage E, et al Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Blood 1998;92:76–82.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Stelitano C, Calvi R, et al Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004;103:2474–2479.
   PubMed Web of Science ®Google Scholar
• Mourad N, Mounier N, Brière J, et al Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de I'Adulte (GELA) trials. Blood 2008;111:4463–4470.
   PubMed Web of Science ®Google Scholar
• Kinoshita T, Hotta T, Tobinai K, et al A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002. Int J Hematol 2004;80:341–350.
   PubMed Web of Science ®Google Scholar
• Mizoroki F, Hirose Y, Sano M, et al A phase II study of VEPA/FEPP chemotherapy for aggressive lymphoma in elderly patients: Japan Clinical Oncology Group Study JCOG9203. Int J Hematol 2006;83:55–62.
   PubMed Web of Science ®Google Scholar
• Itoh K, Ohtsu T, Fukuda H, et al Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505. Ann Oncol 2002;13:1347–1355.
   PubMed Web of Science ®Google Scholar
• Tobinai K, Hotta T. Clinical trials for malignant lymphoma in Japan. Jpn J Clin Oncol 2004;34:369–378.
   PubMed Web of Science ®Google Scholar
• Hotta T, Shimakura Y, Ishizuka N, et al Randomized phase III study of standard CHOP versus biweekly CHOP in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group study, JCOG9809. Proc Am Soc Clin Oncol 2003;22:2271a.
   Google Scholar
• Shimoyama M, Oyama A, Tajima K, et al Differences in clinicopathological characteristics and major prognostic factors between B-lymphoma and peripheral T-lymphoma excluding adult T-cell leukemia/lymphoma. Leuk Lymphoma 1993;10:335–342.
   PubMed Web of Science ®Google Scholar
• Rüdiger T, Weisenburger DD, Anderson JR, et al Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 2002;13:140–149.
   PubMed Web of Science ®Google Scholar
• Armitage J, Vose J, Weisenburger D. International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124–4130.
   PubMed Web of Science ®Google Scholar
• Gascoyne RD, Aoun P, Wu D, et al Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999;93:3913–3921.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Chen YC, Wang CH, et al Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades - should peripheral T-cell lymphoma be considered separately? J Clin Oncol 1989;7:725–731.
   PubMed Web of Science ®Google Scholar
• Hirose Y, Masaki Y, Sawaki T, et al Association of Epstein–Barr virus with human immunodeficiency virus-negative peripheral T-cell lymphomas in Japan. Eur J Haematol 2006;76:109–118.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004;15:1467–1475.
   PubMed Web of Science ®Google Scholar
• Bossard C, Belhadj K, Reyes F, et al Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2007;109:2183–2189.
   PubMed Web of Science ®Google Scholar
• Went P, Agostinelli C, Gallamini A, et al Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 2006;24:2472–2479.
   PubMed Web of Science ®Google Scholar
• Lee J, Suh C, Park YH, et al Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006;24:612–618.
   PubMed Web of Science ®Google Scholar
• Dupuis J, Emile JF, Mounier N, et al Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. Blood 2006;108:4163–4169.
   PubMed Web of Science ®Google Scholar
• Kojima H, Hasegawa Y, Suzukawa K, et al Clinicopathological features and prognostic factors of Japanese patients with ‘peripheral T-cell lymphoma, unspecified’ diagnosed according to the WHO classification. Leuk Res 2004;28:1287–1292.
   PubMed Web of Science ®Google Scholar
• Asano N, Suzuki R, Kagami Y, et al Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am J Surg Pathol 2005;29:1284–1293.
   PubMed Web of Science ®Google Scholar
• Tsuchiya T, Ohshima K, Karube K, et al Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL. Blood 2004;103:236–241.
   PubMed Web of Science ®Google Scholar
• Ohshima K, Karube K, Kawano R, et al Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression: analysis of prognosis. Int J Oncol 2004;25:605–613.
   PubMed Web of Science ®Google Scholar
• Cuadros M, Dave SS, Jaffe ES, et al Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. J Clin Oncol 2007;25:3321–3329.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim BS, Choi CW, et al Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Ann Oncol 2007;18:1382–1387.
   PubMed Web of Science ®Google Scholar
• Kim WY, Jeon YK, Kim TM, et al Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma. Ann Oncol 2009;20:1688–1696.
   PubMed Web of Science ®Google Scholar
• Rodríguez J, Conde E, Gutiérrez A, et al The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica 2007;92:1067–1074.
   PubMed Web of Science ®Google Scholar